Uveal Melanoma Overview

Save information for later
Sign Up

Learn About Uveal Melanoma

What is the definition of Uveal Melanoma?
Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract. The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases of Intraocular melanoma develop in the choroid, called choroidal melanoma. The ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms.
What are the alternative names for Uveal Melanoma?
  • Intraocular melanoma
  • Melanoma of the Uvea
  • Uveal melanoma
Who are the top Uveal Melanoma Local Doctors?
Tara A. Mccannel
Elite in Uveal Melanoma
Dr. Tara A. Mccannel
Ophthalmology
Elite in Uveal Melanoma
Dr. Tara A. Mccannel
Ophthalmology

Jules Stein Eye Institute Medical Group

622 W Duarte Rd, Suite 101, 
Arcadia, CA 
323-442-7122
Languages Spoken:
English
See accepted insurances

Tara Mccannel is an Ophthalmologist in Arcadia, California. Dr. Mccannel is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Melanoma of the Eye, Uveal Melanoma, Metastatic Uveal Melanoma, Vitrectomy, and Cataract Removal.

Elite in Uveal Melanoma
Dr. Prithvi Mruthyunjaya
Ophthalmology
Elite in Uveal Melanoma
Dr. Prithvi Mruthyunjaya
Ophthalmology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
650-723-4000
Languages Spoken:
English
See accepted insurances

Prithvi Mruthyunjaya is an Ophthalmologist in Stanford, California. Dr. Mruthyunjaya is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Melanoma of the Eye, Uveal Melanoma, Retinal Detachment, Vitrectomy, and Trabeculectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Richard D. Carvajal
Elite in Uveal Melanoma
Dr. Richard D. Carvajal
Oncology
Elite in Uveal Melanoma
Dr. Richard D. Carvajal
Oncology

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
516-734-8900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Carvajal is an Oncologist in Lake Success, New York. Dr. Carvajal is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Tissue Biopsy.

View All Doctors
What are the latest Uveal Melanoma Clinical Trials?
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Biological
Study Phase: Phase 2/Phase 3

Summary: The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center